This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Pharmaceutical Pricing and Reimbursement in
China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures
Summary GBI Research, the leading business intelligence provider, has released its latest research "Pharmaceutical Pricing and Reimbursement in
China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures". The report provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in
China with key data, information and analysis of pricing and reimbursement steps. The report closely scrutinizes major changes in the pharmaceuticals-related pricing and reimbursement scene in
China, due to the implementation of the 2009 Healthcare Reform.
Pricing and reimbursement is of paramount importance in
China because of the rapidly rising expenditure on drugs. These issues become more acute because of the large population in
China, and its associated effects on expenditure on drugs. Although the rapidly growing population and shift towards urbanization offer a large market for drug manufacturers, the market is tempered by the pricing and reimbursement system in
China. Challenges faced by companies entering the Chinese pharmaceutical market include government price controls, extensive retail mark-ups, and wide regional variations in insurance.
Pharmaceutical price and pharmaceutical quantity are major factors contributing to healthcare expenditure. The control of retail prices alone is not effective in containing healthcare expenditures; it is also essential to prescribe efficient pharmaceutical utilization. Efficient pharmaceutical utilization is achieved by the use of appropriate reimbursement mechanisms, and a prospective payment system. This cost-driving reimbursement mechanism is incompatible with the goal of containing health-care costs. The reform of the reimbursement mechanism therefore plays a vital role in the changing incentives to the providers. The new reimbursement mechanism provides incentives to healthcare professionals, encouraging efficiency and cost savings when using all health resources, including drugs. The new reimbursement mechanism is an effective countermeasure for the Chinese healthcare system, which is plagued by over-prescription, abuse of quality technology services and cost shifting. A large part of the pharmaceutical market growth is propelled by the expansion of the public sector health insurance coverage, which also includes a greater reimbursement of drugs.